Literature DB >> 28066648

Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites?

Ikuo Sekine1.   

Abstract

Entities:  

Year:  2016        PMID： 28066648      PMCID： PMC5179411          DOI： 10.21037/jtd.2016.11.65

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  21 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?

Authors:  Joshua Bauml; Rosemarie Mick; Yu Zhang; Christopher D Watt; Anil Vachani; Charu Aggarwal; Tracey Evans; Corey Langer
Journal:  Lung Cancer       Date:  2013-06-24       Impact factor: 5.705

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

5.  Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.

Authors:  Conor E Steuer; Madhusmita Behera; Lynne Berry; Sungjin Kim; Michael Rossi; Gabriel Sica; Taofeek K Owonikoko; Bruce E Johnson; Mark G Kris; Paul A Bunn; Fadlo R Khuri; Edward B Garon; Suresh S Ramalingam
Journal:  Cancer       Date:  2015-12-22       Impact factor: 6.860

6.  Racial diversity of actionable mutations in non-small cell lung cancer.

Authors:  Aliccia Bollig-Fischer; Wei Chen; Shirish M Gadgeel; Angela S Wenzlaff; Michele L Cote; Ann G Schwartz; Gerold Bepler
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

7.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

8.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Authors:  Yi-Long Wu; Caicun Zhou; Cheng-Ping Hu; Jifeng Feng; Shun Lu; Yunchao Huang; Wei Li; Mei Hou; Jian Hua Shi; Kye Young Lee; Chong-Rui Xu; Dan Massey; Miyoung Kim; Yang Shi; Sarayut L Geater
Journal:  Lancet Oncol       Date:  2014-01-15       Impact factor: 41.316

9.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

10.  Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

Authors:  Norihiro Yamaguchi; Paul A Vanderlaan; Erik Folch; David H Boucher; Hannah M Canepa; Michael S Kent; Sidharta P Gangadharan; Adnan Majid; Olivier N Kocher; Michael A Goldstein; Mark S Huberman; Daniel B Costa
Journal:  Lung Cancer       Date:  2013-08-07       Impact factor: 5.705
View more
  1 in total

1.  Non-small cell lung cancer genomics around the globe: focus on ethnicity.

Authors:  Luiz H Araujo; David P Carbone
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.